Werewolf Therapeutics Inc Stock price
Is Werewolf Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Werewolf Therapeutics Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a Werewolf Therapeutics Inc forecast:
Analyst Opinions
8 Analysts have issued a Werewolf Therapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Werewolf Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Werewolf Therapeutics Inc Stock News
Company Profile
Werewolf Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Dr. Hicklin |
| Employees | 39 |
| Founded | 2017 |
| Website | werewolftx.com |


